These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
244 related items for PubMed ID: 17452893
1. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Cransberg K, Cornelissen M, Lilien M, Van Hoeck K, Davin JC, Nauta J. Transplantation; 2007 Apr 27; 83(8):1041-7. PubMed ID: 17452893 [Abstract] [Full Text] [Related]
2. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P, Cyclosporine Withdrawal Study Group. J Am Soc Nephrol; 2005 Jul 27; 16(7):2234-40. PubMed ID: 15917338 [Abstract] [Full Text] [Related]
3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Sollinger HW. Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033 [Abstract] [Full Text] [Related]
4. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Leonhardt M, Fitzsimmons WE. Transplantation; 2003 Jun 27; 75(12):2048-53. PubMed ID: 12829910 [Abstract] [Full Text] [Related]
5. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation; 1996 Mar 15; 61(5):722-9. PubMed ID: 8607174 [Abstract] [Full Text] [Related]
6. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study. Thierry A, Le Meur Y, Ecotière L, Abou-Ayache R, Etienne I, Laurent C, Vuiblet V, Colosio C, Bouvier N, Aldigier JC, Rerolle JP, Javaugue V, Gand E, Bridoux F, Essig M, Hurault de Ligny B, Touchard G. Transpl Int; 2016 Jan 15; 29(1):23-33. PubMed ID: 26729582 [Abstract] [Full Text] [Related]
7. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C. J Am Soc Nephrol; 2005 Aug 15; 16(8):2509-16. PubMed ID: 15987748 [Abstract] [Full Text] [Related]
8. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Le Meur Y, Thierry A, Glowacki F, Rerolle JP, Garrigue V, Ouali N, Heng AE, Delahousse M, Albano L, Lang P, Couzi L, Jaureguy M, Lebranchu Y, Mousson C, Glotz D, Kessler M, Vrtovsnik F, Rouanet S, Tagieva N, Kamar N. Transplantation; 2011 Dec 15; 92(11):1244-51. PubMed ID: 22067312 [Abstract] [Full Text] [Related]
9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW. Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719 [Abstract] [Full Text] [Related]
10. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW. J Am Soc Nephrol; 2002 Feb 15; 13(2):536-543. PubMed ID: 11805185 [Abstract] [Full Text] [Related]
11. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group. Transplantation; 2005 Apr 15; 79(7):807-14. PubMed ID: 15818323 [Abstract] [Full Text] [Related]
13. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Höcker B, John U, Plank C, Wühl E, Weber LT, Misselwitz J, Rascher W, Mehls O, Tönshoff B. Transplantation; 2004 Jul 27; 78(2):228-34. PubMed ID: 15280683 [Abstract] [Full Text] [Related]
14. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S. Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352 [Abstract] [Full Text] [Related]
15. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Höcker B, Weber LT, Bunchman T, Rashford M, Tönshoff B, Tricontinental MMF Suspension Study Group. Pediatr Transplant; 2005 Aug 20; 9(4):504-11. PubMed ID: 16048604 [Abstract] [Full Text] [Related]